The following work describes the development of a novel noninvasive transmucosal drug delivery system, the chitosan sponge matrix (CSM). It is composed of cationic chitosan (CS) nanoparticles (NPs) that encapsulate cisplatin (CDDP) embedded within a polymeric mucoadhesive CS matrix. CSM is designed to swell up when exposed to moisture, facilitating release of the NPs via diffusion across the matrix. CSM is intended to be administered topically and locally to mucosal tissues, with its initial indication being oral cancer (OC). Currently, intravenous (IV) administered CDDP is the gold standard chemotherapeutic agent used in the treatment of OC. However, its clinical use has been limited by its renal and hemotoxicity profile. We aim to locally administer CDDP via encapsulation in CS NPs and deliver them directly to the oral cavity with CSM. It is hypothesized that such a delivery device will greatly reduce any systemic toxicity and increase antitumor efficacy. This paper describes the methods for developing CSM and maintaining the integrity of CDDP NPs embedded in the CSM.
Issue Section:
Research Papers
References
1.
Ceschel
, G. C.
, Maffei
, P.
, Sforzini
, A.
, Borgia
, S. L.
, Yasin
, A.
, and Ronchi
, C.
, 2002
, “In Vitro Permeation Through Porcine Buccal Mucosa of Caffeic Acid Phenetyl Ester (CAPE) From a Topical Mucoadhesive Gel Containing Propolis
,” Fitoterapia
, 73
, pp. S44
–S52
.10.1016/S0367-326X(02)00190-92.
Mura
, P.
, Corti
, G.
, Cirri
, M.
, Maestrelli
, F.
, Mennini
, N.
, and Bragagni
, M.
, 2010
, “Development of Mucoadhesive Films for Buccal Administration of Flufenamic Acid: Effect of Cyclodextrin Complexation
,” J. Pharm. Sci.
, 99
(7
), pp. 3019
–3029
.10.1002/jps.220683.
Ceschel
, G. C.
, Maffei
, P.
, Borgia
, S. L.
, and Ronchi
, C.
, 2001
, “Design and Evaluation of Buccal Adhesive Hydrocortisone Acetate (HCA) Tablets
,” Drug Delivery
, 8
(3
), pp. 161
–171
10.1080/107175401316906937.4.
Odukoya
, O.
, Hawach
, F.
, and Shklar
, G.
, 1985
, “Retardation of Experimental Oral Cancer by Topical Vitamin E
,” Nutr. Cancer
, 6
(2
), pp. 98
–104
.10.1080/016355885095138135.
Senel
, S.
, Kremer
, M.
, Nagy
, K.
, and Squier
, C.
, 2001
, “Delivery of Bioactive Peptides and Proteins Across Oral (Buccal) Mucosa
,” Curr. Pharm. Biotechnol.
, 2
(2
), pp. 175
–186
.10.2174/13892010133787346.
Van Roey
, J.
, Haxaire
, M.
, Kamya
, M.
, Lwanga
, I.
, and Katabira
, E.
, 2004
, “Comparative Efficacy of Topical Therapy With a Slow-Release Mucoadhesive Buccal Tablet Containing Miconazole Nitrate Versus Systemic Therapy With Ketoconazole in HIV-Positive Patients With Oropharyngeal Candidiasis
,” JAIDS J. Acquired Immune Defic. Syndr.
, 35
(2
), pp. 144
–150
.10.1097/00126334-200402010-000077.
Wong
, H. L.
, Bendayan
, R.
, Rauth
, A. M.
, Li
, Y.
, and Wu
, X. Y.
, 2007
, “Chemotherapy With Anticancer Drugs Encapsulated in Solid Lipid Nanoparticles
,” Adv. Drug Delivery Rev.
, 59
(6
), pp. 491
–504
.10.1016/j.addr.2007.04.0088.
Illum
, L.
, 1998
, “Chitosan and Its Use as a Pharmaceutical Excipient
,” Pharm. Res.
, 15
(9
), pp. 1326
–1331
.10.1023/A:10119290166019.
Santiago de Alvarenga
, E.
, 2011
, “Characterization and Properties of Chitosan
,” Material Science Biotechnology of Bipolymers
, pp. 91
–108
10.5772/17020.10.
Garcia-Fuentes
, M.
, and Alonso
, M. J.
, 2012
, “Chitosan-Based Drug Nanocarriers: Where Do We Stand?
,” J. Controlled Release
, 161
(2
), pp. 496
–504
.10.1016/j.jconrel.2012.03.01711.
Simeonova
, M.
, Velichkova
, R.
, Ivanova
, G.
, Enchev
, V.
, and Abrahams
, I.
, 2003
, “Poly (Butylcyanoacrylate) Nanoparticles for Topical Delivery of 5-Fluorouracil
,” Int. J. Pharm.
, 263
(1
), pp. 133
–140
.10.1016/S0378-5173(03)00373-912.
Giannola
, L. I.
, De Caro
, V.
, Giandalia
, G.
, Siragusa
, M. G.
, Paderni
, C.
, Campisi
, G.
, and Florena
, A. M.
, 2010
, “5-Fluorouracil Buccal Tablets for Locoregional Chemotherapy of Oral Squamous Cell Carcinoma: Formulation, Drug Release and Histological Effects on Reconstituted Human Oral Epithelium and Porcine Buccal Mucosa
,” Curr. Drug Delivery
, 7
(2
), pp. 109
–117
.10.2174/15672011079101179213.
Westra
, W. H.
, 2009
, “The Changing Face of Head and Neck Cancer in the 21st Century: The Impact of HPV on the Epidemiology and Pathology of Oral Cancer
,” Head Neck Pathol.
, 3
(1
), pp. 78
–81
.10.1007/s12105-009-0100-y14.
National Cancer Institute
, 2015
, Cancer of the Oral Cavity and Pharynx
, Surveillance, Epidemiology, and End Results Program Turning Cancer Data Into Discovery, http://seer.cancer.gov/statfacts/html/oralcav.html, Last accessed January 2, 2015.15.
Rischin
, D.
, 2005
, “Induction Chemotherapy in Head and Neck Cancer
,” Squamous Cell Head and Neck Cancer
, Humana Press
, New York
, pp. 165
–170
10.1007/978-1-59259-938-7_11.16.
Bachaud
, J. M.
, Cohen-Jonathan
, E.
, Alzieu
, C.
, David
, J. M.
, Serrano
, E.
, and Daly-Schveitzer
, N.
, 1996
, “Combined Postoperative Radiotherapy and Weekly Cisplatin Infusion for Locally Advanced Head and Neck Carcinoma: Final Report of a Randomized Trial
,” Int. J. Radiat. Oncol. Biol. Phys.
, 36
(5
), pp. 999
–1004
.10.1016/S0360-3016(96)00430-017.
Ihde
, D. C.
, Mulshine
, J. L.
, Kramer
, B. S.
, Steinberg
, S. M.
, Linnoila
, R. I.
, Gazdar
, A. F.
, Edison
, M.
, Phelps
, R. M.
, Lesar
, M.
, and Phares
, J. C.
, 1994
, “Prospective Randomized Comparison of High-Dose and Standard-Dose Etoposide and Cisplatin Chemotherapy in Patients With Extensive-Stage Small-Cell Lung Cancer
,” J. Clin. Oncol.
, 12
(10
), pp. 2022
–2034
10.1093/jnci/djg017.18.
Studer
, U. E.
, Bacchi
, M.
, Biedermann
, C.
, Jaeger
, P.
, Kraft
, R.
, Mazzucchelli
, L.
, Markwalder
, R.
, Senn
, E.
, and Sonntag
, R. W.
, 1994
, “Adjuvant Cisplatin Chemotherapy Following Cystectomy for Bladder Cancer: Results of a Prospective Randomized Trial
,” J. Urol.
, 152
(1
), pp. 81
–84
10.1016/j.eururo.2013.08.033.19.
Pearcey
, R.
, Brundage
, M.
, Drouin
, P.
, Jeffrey
, J.
, Johnston
, D.
, Lukka
, H.
, MacLean
, G.
, Souhami
, L.
, Stuart
, G.
, and Tu
, D.
, 2002
, “Phase III Trial Comparing Radical Radiotherapy With and Without Cisplatin Chemotherapy in Patients With Advanced Squamous Cell Cancer of the Cervix
,” J. Clin. Oncol.
, 20
(4
), pp. 966
–972
.10.1200/JCO.20.4.96620.
Blair
, B. G.
, Larson
, C. A.
, Adams
, P. L.
, Abada
, P. B.
, Pesce
, C. E.
, Safaei
, R.
, and Howell
, S. B.
, 2011
, “Copper Transporter 2 Regulates Endocytosis and Controls Tumor Growth and Sensitivity to Cisplatin In Vivo
,” Mol. Pharmacol.
, 79
(1
), pp. 157
–166
.10.1124/mol.110.06841121.
Sharp
, S. Y.
, Rogers
, P. M.
, and Kelland
, L. R.
, 1995
, “Transport of Cisplatin and Bis-Acetato-Ammine-Dichlorocyclohexylamine Platinum (IV)(JM216) in Human Ovarian Carcinoma Cell Lines: Identification of a Plasma Membrane Protein Associated With Cisplatin Resistance
,” Clin. Cancer Res.
, 1
(9
), pp. 981
–989
10.3892/or.2014.3257.22.
Fuertes
, M. A.
, Castilla
, J.
, Alonso
, C.
, and Perez
, J. M.
, 2003
, “Cisplatin Biochemical Mechanism of Action: From Cytotoxicity to Induction of Cell Death Through Interconnections Between Apoptotic and Necrotic Pathways
,” Curr. Med. Chem.
, 10
(3
), pp. 257
–266
.10.2174/092986703336848423.
Hamers
, F. P. T.
, Gispen
, W. H.
, and Neijt
, J. P.
, 1991
, “Neurotoxic Side-Effects of Cisplatin
,” Eur. J. Cancer Clin. Oncol.
, 27
(3
), pp. 372
–376
.10.1016/0277-5379(91)90549-S24.
Von Hoff
, D. D.
, Schilsky
, R.
, Reichert
, C. M.
, Reddick
, R. L.
, Rozencweig
, M.
, Young
, R. C.
, and Muggia
, F. M.
, 1978
, “Toxic Effects of Cis-Dichlorodiammineplatinum (II) in Man
,” Cancer Treat. Rep.
, 63
(9–10
) pp. 1527
–1531
10.1007/BF00254137742.25.
Lau
, J. K.
, and Deubel
, D. V.
, 2005
, “Loss of Amine From Platinum (II) Complexes: Implications for Cisplatin Inactivation, Storage, and Resistance
,” Chem.- Eur. J.
, 11
(9
), pp. 2849
–2855
.10.1002/chem.20040105326.
Jain
, R. K.
, 2001
, “Normalizing Tumor Vasculature With Anti-Angiogenic Therapy: A New Paradigm for Combination Therapy
,” Nat. Med.
, 7
(9
), pp. 987
–989
.10.1038/nm0901-98727.
Lin
, J.
, and Alexander-Katz
, A.
, 2013
, “Cell Membranes Open ‘Doors' for Cationic Nanoparticles/Biomolecules: Insights Into Uptake Kinetics
,” ACS Nano.
, 7
(12
), pp. 10799
–10808
.10.1021/nn404055328.
Fernandez-Urrusuno
, R.
, Calvo
, P.
, Remunan-Lopez
, C.
, Vila-Jato
, L.
, and Alonso
, M.
, 1999
, “Enhancement of Nasal Absorption of Insulin Using Chitosan Nanoparticles
,” Pharm. Res.
, 16
(10
), pp. 1576
–1581
.10.1023/A:101890870544629.
Shojaei
, A. H.
, 1998
, “Buccal Mucosa as a Route for Systemic Drug Delivery: A Review
,” J. Pharm. Pharm. Sci.
, 1
(1
), pp. 15
–30
10.5138/ijdd.v3i4.426.30.
Nakamura
, T.
, and Kinoshita
, S.
, 2003
, “Ocular Surface Reconstruction Using Cultivated Mucosal Epithelial Stem Cells
,” Cornea
, 22
(7
), pp. S75
–S80
.10.1097/00003226-200310001-0001131.
Berners-Price
, S. J.
, Frenkiel
, T. A.
, Frey
, U.
, Ranford
, J.
, and Sadler
, P. J.
, 1992
, “Hydrolysis Products of Cisplatin: pKa Determinations Via [1H, 15N] NMR Spectroscopy
,” J. Chem. Soc., Chem. Commun.
, 1992
(10
), pp. 789
–791
.10.1039/c3992000078932.
Corden
, B. J.
, 1987
, “Reaction of Platinum (II) Antitumor Agents With Sulfhydral Compounds and the Implications for Nephrotoxicity
,” Inorg. Chim. Acta
, 137
(1
), pp. 125
–130
.10.1016/S0020-1693(00)87131-533.
Galluzzi
, L.
, Senovilla
, L.
, Vitale
, I.
, Michels
, J.
, Martins
, I.
, Kepp
, O.
, Castedo
, M.
, and Kroemer
, G.
, 2012
, “Molecular Mechanisms of Cisplatin Resistance
,” Oncogene
, 31
(15
), pp. 1869
–1883
.10.1038/onc.2011.38434.
Long
, D. F.
, and Repta
, A. J.
, 1981
, “Review Article Cisplatin: Chemistry, Distribution and Biotransformation
,” Biopharm. Drug Dispos.
, 2
(1
), pp. 1
–16
.10.1002/bdd.251002010235.
Bose
, R. N.
, Cornelius
, R. D.
, and Viola
, R. E.
, 1985
, “Kinetics and Mechanisms of Platinum (II)-Promoted Hydrolysis of Inorganic Polyphosphates
,” Inorg. Chem.
, 24
(24
), pp. 3989
–3996
.10.1021/ic00218a00636.
Shafee
, N.
, Smith
, C. R.
, Wei
, S.
, Kim
, Y.
, Mills
, G. B.
, Hortobagyi
, G. N.
, Stanbridge
, E. J.
, and Lee
, E. Y.-H. P.
, 2008
, “Cancer Stem Cells Contribute to Cisplatin Resistance in Brca1/p53–Mediated Mouse Mammary Tumors
,” Cancer Res.
, 68
(9
), pp. 3243
–3250
.10.1158/0008-5472.CAN-07-548037.
Dass
, C. R.
, and Choong
, P. F. M.
, 2008
, “The Use of Chitosan Formulations in Cancer Therapy
,” J. Microencapsulation
, 25
(4
), pp. 275
–279
.10.1080/0265204080197046138.
Huang
, M.
, Khor
, E.
, and Lim
, L.-Y.
, 2004
, “Uptake and Cytotoxicity of Chitosan Molecules and Nanoparticles: Effects of Molecular Weight and Degree of Deacetylation
,” Pharm. Res.
, 21
(2
), pp. 344
–353
.10.1023/B:PHAM.0000016249.52831.a539.
Agnihotri
, S. A.
, Mallikarjuna
, N. N.
, and Aminabhavi
, T. M.
, 2004
, “Recent Advances on Chitosan-Based Micro-and Nanoparticles in Drug Delivery
,” J. Controlled Release
, 100
(1
), pp. 5
–28
.10.1016/j.jconrel.2004.08.01040.
Freier
, T.
, Koh
, H. S.
, Kazazian
, K.
, and Shoichet
, M. S.
, 2005
, “Controlling Cell Adhesion and Degradation of Chitosan Films by N-Acetylation
,” Biomaterials
, 26
(29
), pp. 5872
–5878
.10.1016/j.biomaterials.2005.02.03341.
Pan
, Y.
, Li
, Y. J.
, Zhao
, H. Y.
, Zheng
, J. M.
, Xu
, H.
, Wei
, G.
, Hao
, J. S.
, and Cui
, F. D.
, 2002
, “Bioadhesive Polysaccharide in Protein Delivery System: Chitosan Nanoparticles Improve the Intestinal Absorption of Insulin In Vivo
,” Int. J. Pharm.
, 249
(1
), pp. 139
–147
.10.1016/S0378-5173(02)00486-6Copyright © 2014 by ASME
You do not currently have access to this content.
